MXPA03002479A - Polipeptidos de nectina, polinucleotidos, metodos para elaborarlos y uso de los mismos. - Google Patents

Polipeptidos de nectina, polinucleotidos, metodos para elaborarlos y uso de los mismos.

Info

Publication number
MXPA03002479A
MXPA03002479A MXPA03002479A MXPA03002479A MXPA03002479A MX PA03002479 A MXPA03002479 A MX PA03002479A MX PA03002479 A MXPA03002479 A MX PA03002479A MX PA03002479 A MXPA03002479 A MX PA03002479A MX PA03002479 A MXPA03002479 A MX PA03002479A
Authority
MX
Mexico
Prior art keywords
polynucleotides
methods
polypeptides
making
nectin
Prior art date
Application number
MXPA03002479A
Other languages
English (en)
Inventor
Adel Youakim
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of MXPA03002479A publication Critical patent/MXPA03002479A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)

Abstract

La Invencion se refiere a polinucleotidos y polipeptidos de nectina, a metodos para elaborar tales polipeptidos y polinucleotidos, y a metodos para utilizar tales polipeptidos y polinucleotidos para modular la adhesion celular, migracion celular, y angiogenesis, para tratar condiciones relacionadas con la adhesion celular incluyendo proliferacion de la celula epitelial y endotelial, migracion y funcion de barrera, y para identificar agentes que alteran las actividades del polipeptido de nectlna.
MXPA03002479A 2000-10-05 2001-10-05 Polipeptidos de nectina, polinucleotidos, metodos para elaborarlos y uso de los mismos. MXPA03002479A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23855700P 2000-10-05 2000-10-05
PCT/US2001/031392 WO2002028902A2 (en) 2000-10-05 2001-10-05 Nectin polypeptides, polynucleotides, methods of making and use thereof

Publications (1)

Publication Number Publication Date
MXPA03002479A true MXPA03002479A (es) 2004-05-24

Family

ID=22898428

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03002479A MXPA03002479A (es) 2000-10-05 2001-10-05 Polipeptidos de nectina, polinucleotidos, metodos para elaborarlos y uso de los mismos.

Country Status (7)

Country Link
US (2) US7175849B2 (es)
EP (1) EP1325032A2 (es)
JP (1) JP2004528008A (es)
AU (2) AU2002213053B2 (es)
CA (1) CA2423462A1 (es)
MX (1) MXPA03002479A (es)
WO (1) WO2002028902A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7129061B1 (en) * 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
MXPA02004862A (es) * 1999-11-15 2003-01-28 Pharma Mar Sa Tratamiento de aplidina para canceres.
RU2003113210A (ru) * 2000-10-12 2004-11-27 Фарма Мар, С.А. (Es) Лечение раковых заболеваний
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
EP1402054A4 (en) * 2001-05-25 2005-08-17 Immunex Corp ATTRACTIN / MAHOGANY POLYPEPTIDES, POLYNUCLEOTIDES, ANTIBODIES AND METHODS OF USE
ATE411036T1 (de) * 2001-10-19 2008-10-15 Pharma Mar Sa Verwendung von aplidine in der behandlung von pankreaskrebs
AU2003230874A1 (en) * 2002-04-16 2003-11-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003243151A1 (en) * 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
AU2008202217B2 (en) * 2002-08-16 2012-07-26 Agensys, Inc. Nucleic acids and corresponding proteins entitled 191PAD12(b) useful in treatment and detection of cancer
FR2845693B1 (fr) * 2002-10-15 2005-04-01 France Hybrides Procede pour produire un mammifere rendu resistant a une infection par un alpha herpes virus ainsi que mammifere obtenu par la mise en oeuvre de ce procede et descendant d'un tel mammifere
FR2845692A1 (fr) * 2002-10-15 2004-04-16 France Hybrides Procede pour produire un mammifere rendu resistant a une infection par un alpha herpes virus par transgenese germinale ainsi que mammifere obtenu par la mise en oeuvre de ce procede
SI1603584T1 (sl) * 2003-03-12 2009-02-28 Dana Farber Cancer Inst Inc Aplidin za zdravljenje multiple mieloma
WO2005097204A1 (ja) * 2004-04-09 2005-10-20 Takeda Pharmaceutical Company Limited 癌の予防・治療剤
US20080268476A1 (en) * 2004-05-12 2008-10-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nectin 4 (N4) as a Marker for Cancer Prognosis
FR2873876B1 (fr) * 2004-07-27 2006-11-17 Cnes Epic Procede d'etalement de spectre avec effacement de sous- bandes
WO2006045076A2 (en) * 2004-10-19 2006-04-27 Massachusetts Institute Of Technology Virus scaffold for self-assembled, flexible and light lithium battery
US20090124993A1 (en) 2005-02-17 2009-05-14 Burkly Linda C Treating neurological disorders
US20090068102A1 (en) * 2005-02-17 2009-03-12 Biogen Idec Ma Inc. Treating stroke
EP1885388B1 (en) 2005-05-10 2013-09-11 Biogen Idec MA Inc. Treating and evaluating inflammatory disorders
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
CA2639119A1 (en) * 2005-10-07 2007-04-19 Takeda Pharmaceutical Company Limited Agent for preventing/treating cancer
BRPI0717024A2 (pt) 2006-10-06 2014-03-11 Takeda Pharmaceutical Anticorpo, célula de hibridoma, agente de diagnótico, medicamento, métodos para prevenir/tratar câncer, para induzir apoptose células cancerosas , para inibir crescimento de células cancerosas e para destruir células cancerosas, uso de um anicorpo monoclonal e agente para prevenir ou tratar câncer de mama.
US8663210B2 (en) 2009-05-13 2014-03-04 Novian Health, Inc. Methods and apparatus for performing interstitial laser therapy and interstitial brachytherapy
ES2874306T3 (es) 2010-09-29 2021-11-04 Agensys Inc Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12
WO2012098465A1 (en) * 2011-01-18 2012-07-26 Dalhousie University Pvrl4 (nectin 4) is a receptor for measles virus
JP2015520192A (ja) * 2012-06-06 2015-07-16 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｈｉｐｐｏ経路を調節する結合剤およびその使用
CN104418951B (zh) * 2013-08-29 2017-07-18 北京伟德杰生物科技有限公司 人Nectin‑2蛋白的应用
KR101997142B1 (ko) * 2017-09-06 2019-07-08 순천향대학교 산학협력단 넥틴-4를 포함하는 천식 진단용 바이오마커 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6472520B2 (en) * 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
JP3623710B2 (ja) 2000-03-09 2005-02-23 独立行政法人科学技術振興機構 蛋白質ネクチン−３

Also Published As

Publication number Publication date
EP1325032A2 (en) 2003-07-09
US7175849B2 (en) 2007-02-13
AU2002213053B2 (en) 2006-12-21
JP2004528008A (ja) 2004-09-16
CA2423462A1 (en) 2002-04-11
US20070117754A1 (en) 2007-05-24
WO2002028902A2 (en) 2002-04-11
US20030044893A1 (en) 2003-03-06
AU1305302A (en) 2002-04-15
WO2002028902A3 (en) 2002-12-05

Similar Documents

Publication Publication Date Title
MXPA03002479A (es) Polipeptidos de nectina, polinucleotidos, metodos para elaborarlos y uso de los mismos.
NO20001600L (no) Apolipoprotein A-1-agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser
IL143596A0 (en) Vascular endothelial cell growth factor antagonists and uses thereof
DE69823046D1 (de) Praktische in vitro sialylierung von rekombinanten glykpproteinen
ATE342262T1 (de) Neue integrin rezeptor antagonisten
ATE460429T1 (de) Polypeptide enthaltend extrazellulären domäne von il-20ra und/oderr il-20rb
DE69822840D1 (de) Säugetier zytokinrezeptor-11
HK1049501B (zh) 用鋅指蛋白使基因組產生影響官能的特性
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
DK1017715T3 (da) Kimært polypeptid der omfatter fragment B af shiga-toksin og peptider af terapeutisk interesse
AU8497701A (en) Claudin polypeptides
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
ATE280777T1 (de) Bradykinin-antagonist peptide mit n- substituierten glycinen
DE69735502D1 (de) Mutanten des lag-3 proteins, ihre expression und verwendung
HUP0402496A2 (hu) Módosított polipeptidek
TR200003347T2 (tr) Neisseria meningitidis'denBASB029 polinükleotidleri ve polipeptidler
DE60236212D1 (de) Neue isoform des gefässendothelzell wachstumshemmers (vegi)
MX2022003531A (es) Polipeptidos de fusion dap10/dap12.
DE59801230D1 (de) Endothelin-rezeptorantagonisten zur bekämpfung von hyperlipidämie
NO20006026L (no) Fremgangsmåter og blandinger for modulering av angiogenese ved bruk av tyrosin kinase SRC
ATE279923T1 (de) Urotensin-ii rezeptorantagonisten
WO2001016181A3 (en) Crystal structures of domains of receptor protein tyrosine kinases and their ligands
DK0826054T3 (da) Ekspression af glycosyltransferase i Aspergillus
WO2002088358A3 (en) Human fibroblast growth factor-related compositions
DE60221501D1 (de) Bfit (brown fat inducible thioesterase) polypeptide und polynukleotide und ihre verwendung